Loading
IARC estimates 7,992 new cancer cases and 4,993 cancer deaths in Burundi in 2024; the commonest new cancers are cervix uteri, breast and prostate. This page is assembled automatically from OnCo's data, and says what OnCo does not yet hold.
Built partly from other countries' data. IARC's method code for Burundi's incidence estimate is 5: rates based on incidence estimates or registry data from neighbouring countries. Read the figures as a regional estimate, not a count.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Cervix uteri | 1,242 | 31.6 | Cervical cancer |
| Breast | 966 | 23.5 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Prostate | 912 | 39.1 | Prostate cancer |
| Colorectum | 521 | 8.1 | Colorectal cancer |
| Oesophagus | 460 | 7.6 | Oesophageal cancer |
| Liver and intrahepatic bile ducts | 422 | 6.2 | Hepatocellular carcinoma |
| Stomach | 377 | 6.2 | Gastric & gastro-oesophageal junction cancer |
| Leukaemia | 315 | 3.2 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Non-Hodgkin lymphoma | 301 | 3.4 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Kaposi sarcoma | 240 | 2.5 | Kaposi sarcoma |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Cervix uteri | 732 | 19.2 | Cervical cancer |
| Prostate | 556 | 24.3 | Prostate cancer |
| Breast | 456 | 11.8 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Oesophagus | 425 | 7.2 | Oesophageal cancer |
| Liver and intrahepatic bile ducts | 379 | 5.8 | Hepatocellular carcinoma |
| Stomach | 303 | 5.3 | Gastric & gastro-oesophageal junction cancer |
| Colorectum | 293 | 4.9 | Colorectal cancer |
| Leukaemia | 212 | 2.3 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Trachea, bronchus and lung | 167 | 2.9 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Non-Hodgkin lymphoma | 153 | 2.0 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
No trial record in OnCo lists a site in Burundi. OnCo reads sites from ClinicalTrials.gov; studies registered only elsewhere are searchable through the WHO International Clinical Trials Registry Platform.
OnCo holds no institution, company or person in Burundi.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Burundi is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
Burundi is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.